Abstract
A well-defined pathway for the accelerated development and approval of targeted cancer therapies and companion diagnostics would reduce uncertainty, improve efficiency in development and provide an effective incentive for developers.
Original language | English (US) |
---|---|
Pages (from-to) | 79-80 |
Number of pages | 2 |
Journal | Nature Reviews Drug Discovery |
Volume | 10 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2011 |
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery